Determination of the Feasibility of Using Cell-Free DNA (cfDNA) in the Q-Clamp KRAS Codon Specific Mutation Test

<p>KRAS is a proto-oncogene which was first identified in Kirsten rat sarcoma virus. The normal KRAS protein performs an essential function in normal tissue signaling and a mutation of a KRAS gene is an essential step in the development of many cancers. Q-Clamp® KRAS codon specific mutation test is an in vitro real-time qualitative PCR assay for the detection of mutations in the targeted regions and KRAS mutation often serves as a useful marker in drug response. The Q-Clamp® KRAS codon specific mutation test experiment was performed using cell-free extracted DNA (cfDNA) instead of FFPE extracted DNA. The results of the experiment showed a clear difference in the Ct’s between the mutant and internal control. Since the delta Ct’s can be discriminated, the assay showed a positive feasibility of using a cfDNA in the Q-Clamp ® KRAS codon specific mutation test.</p>

Name thesis:degree_name

Master of Science

Level thesis:degree_level

Master's Thesis

Discipline thesis:degree_discipline

Clinical Laboratory Sciences

Year dc:date.available

2018

Author dc:creator

• Garcia, Manuel

Contributors dc:contributor

• Roberta M. Madej, PhD, CLS., MB(ASCP), MBA
• Maria C. DeSousa, JD, MPA, CLS

• Q-Clamp
• Cell-Free DNA
• Medicine and Health Sciences

Repository record dc:identifier

https://scholar.dominican.edu/masters-theses/335

OAI identifier oai:identifier

oai:scholar.dominican.edu:masters-theses-1341